Boca Biolistics Announces Formation of Scientific Advisory Board to Strengthen Clinical and Biospecimen Leadership

Pompano Beach, Florida. January, 2026
Boca Biolistics announced the formation of its Scientific Advisory Board, established in January 2026, reinforcing the company's commitment to scientific excellence, regulatory rigor, and strategic growth across clinical research and biospecimen logistics.
The newly appointed Scientific Advisory Board brings together senior leaders from global biopharma, diagnostics, clinical research, and academic medicine, adding deep expertise across drug development, molecular diagnostics, oncology, and laboratory medicine.

Scientific Advisory Board Members
Harold Alvarez, MD
Medical Director of the Cell Therapy and Immunotherapy Laboratory, Miami Cancer Institute (Baptist Health South Florida)
Dr. Alvarez serves as Medical/Laboratory Director of Transfusion Medicine, Apheresis, and Cell & Immunotherapy at Miami Cancer Institute. His expertise spans cellular therapy, flow cytometry, immunohematology, and clinical laboratory operations. He previously held leadership roles at CDI Clinical Discovery Institute, OneBlood, and HCA. His background strengthens Boca's oversight in oncology, immunotherapy, cell therapy, and advanced clinical laboratory integration.

Elisa Cascade
Chief Growth Officer, TrialScreen
2024 Chair, Board of Trustees, ACRP
Former Chief Product Officer at Advarra, Science 37, Clario, and IQVIA
Elisa Cascade is a recognized leader in decentralized clinical trials, eCOA, digital patient engagement, and clinical research operations. She has held executive leadership positions across major clinical research and technology organizations and served as Chair of the Board of Trustees for ACRP (Association of Clinical Research Professionals). Her experience brings strategic insight in product lifecycle management, regulatory-aligned clinical operations, and global sponsor engagement.

James Novotny
Dx/Rx Consultant
Former Group Director, Pharmacodiagnostics, Bristol Myers Squibb
Former Director, Diagnostic Product Development, Roche Molecular Systems
James Novotny brings over three decades of leadership in companion diagnostics and molecular diagnostic product development. At Bristol Myers Squibb, he led pharmacodiagnostics integration across drug development pipelines. During his 18-year tenure at Roche Molecular Systems, he oversaw PCR-based diagnostic product development across virology, oncology, microbiology, and blood screening. His expertise reinforces Boca's strategic alignment across diagnostics, pharmacuticals and assay lifecycle management.

A Foundational Step for Scalable Growth
As Boca Biolistics expands its role across diagnostics, biopharma, and biotechnology sectors, the formation of the Scientific Advisory Board reflects Boca Biolistics' long-term commitment to strengthening quality systems, reducing operational risk, enhancing scientific credibility, and supporting sponsor success across the full product lifecycle.
"The formation of our Scientific Advisory Board marks a pivotal step in Boca Biolistics' evolution. As we continue to expand our capabilities and partnerships across the biotech and pharmaceutical landscape, it is essential that our growth is guided by distinguished scientific leadership" said Valentin Adia, Chief Executive Officer of Boca Biolistics. "This board brings together exceptional expertise that will strengthen our scientific rigor, sharpen our strategic direction, and ensure we remain at the forefront of innovation in biospecimen science and clinical research support." said Valentin Adia, Chief Executive Officer of Boca Biolistics.
In clinical research and biospecimen logistics, scientific oversight is not optional; it is foundational.

Boca Biolistics
5001 NW 13th Ave, Suite H
Pompano Beach, FL, 33064
USA
(954) 449-6126
www.bocabio.com
contact@bocabio.com

Boca Biolistics is a leading provider of biospecimen procurement, clinical trial support, central laboratory services, and biostorage solutions. The company partners with biopharma, diagnostics, and research organizations to accelerate scientific advancement through high-quality, compliant, and reliable specimen services.

This release was published on openPR.